499 Shares in Boston Scientific Co. (NYSE:BSX) Bought by OFI Invest Asset Management

OFI Invest Asset Management acquired a new stake in Boston Scientific Co. (NYSE:BSX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 499 shares of the medical equipment provider’s stock, valued at approximately $36,000.

Other large investors also recently bought and sold shares of the company. SVB Wealth LLC grew its position in shares of Boston Scientific by 12.0% during the fourth quarter. SVB Wealth LLC now owns 14,051 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,503 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Boston Scientific by 5.2% during the fourth quarter. Daiwa Securities Group Inc. now owns 158,722 shares of the medical equipment provider’s stock worth $9,176,000 after buying an additional 7,796 shares during the period. Twin Capital Management Inc. boosted its stake in shares of Boston Scientific by 8.6% during the fourth quarter. Twin Capital Management Inc. now owns 22,996 shares of the medical equipment provider’s stock worth $1,329,000 after buying an additional 1,816 shares during the period. Cambridge Trust Co. grew its holdings in shares of Boston Scientific by 14.7% during the fourth quarter. Cambridge Trust Co. now owns 3,647 shares of the medical equipment provider’s stock worth $211,000 after buying an additional 467 shares during the last quarter. Finally, AIA Group Ltd increased its position in Boston Scientific by 86.4% in the 4th quarter. AIA Group Ltd now owns 22,317 shares of the medical equipment provider’s stock valued at $1,290,000 after acquiring an additional 10,346 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.9 %

NYSE:BSX opened at $78.25 on Monday. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $79.43. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $76.41 and a 200-day simple moving average of $72.01. The company has a market capitalization of $114.80 billion, a PE ratio of 65.76, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter in the previous year, the business posted $0.53 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, equities research analysts expect that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BSX shares. Argus increased their price objective on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Canaccord Genuity Group lifted their price objective on shares of Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Barclays boosted their price objective on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Needham & Company LLC raised their target price on shares of Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, BTIG Research boosted their price target on shares of Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.76.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares of the company’s stock, valued at $2,978,734.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Boston Scientific news, EVP Arthur C. Butcher sold 14,011 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the sale, the executive vice president now directly owns 20,197 shares of the company’s stock, valued at approximately $1,521,641.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the completion of the transaction, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,960 shares of company stock valued at $2,638,984. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.